Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 135.50
+1.00 (0.74%)
Aug 14, 2025, 1:30 PM CST
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 12.21M TWD in the quarter ending June 30, 2025, with 55.61% growth. This brings the company's revenue in the last twelve months to 44.83M, up 26.23% year-over-year. In the year 2024, Caliway Biopharmaceuticals had annual revenue of 44.43M with 14.13% growth.
Revenue (ttm)
44.83M
Revenue Growth
+26.23%
P/S Ratio
4,687.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
210.16B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Oneness Biotech | 112.57M |
| Polaris Group | 87.67M |
| Lumosa Therapeutics | 37.25M |
| Center Laboratories | 1.63B |
| Pegavision | 6.67B |